Novel FLT3 tyrosine kinase inhibitors

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Acute myeloid leukaemia (AML) is an aggressive haematological malignancy that is curable in ∼ 40% of cases. Activating mutations of the receptor tyrosine kinase FLT3 (FMS-like tyrosine kinase-3) are the single most common molecular abnormalities in AML and are associated with a distinctly worse prognosis. In an effort to target this mutation and improve outcomes in this subgroup of AML patients, several novel small-molecule FLT3 tyrosine kinase inhibitors are currently in development. Some of these FLT3 inhibitors are useful only as laboratory tools, while others clearly have clinical potential. These compounds are derived from a wide variety of chemical classes and differ significantly both in their potency and selectivity. This review summarises these developments and examines these novel agents with regard to both the assays used to characterise them and their clinical potential.

Original languageEnglish (US)
Pages (from-to)1951-1962
Number of pages12
JournalExpert Opinion on Investigational Drugs
Issue number12
StatePublished - Dec 2003


  • AML
  • FLT3
  • Kinase inhibitor
  • Tyrosine kinase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Novel FLT3 tyrosine kinase inhibitors'. Together they form a unique fingerprint.

Cite this